Trials / Completed
CompletedNCT05453136
Phase III Study of TS-142 in Patients with Insomnia
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study of TS-142 in Patients with Insomnia Disorder.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,155 (actual)
- Sponsor
- Taisho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, multi-center, placebo-controlled, parallel-group confirmatory study in patients with insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TS-142 5 mg | Participants received repeated doses of 5 mg of TS-142 (oral tablet) |
| DRUG | TS-142 10 mg | Participants received repeated doses of 10 mg of TS-142 (oral tablet) |
| DRUG | Placebo to TS-142 | Participants received repeated doses of placebo to TS-142 (oral tablet) |
Timeline
- Start date
- 2022-08-30
- Primary completion
- 2023-12-05
- Completion
- 2023-12-05
- First posted
- 2022-07-12
- Last updated
- 2025-02-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05453136. Inclusion in this directory is not an endorsement.